第26届圣安东尼奥乳腺癌会议综述
被引量：1
Review of the 26th San Antonio breast cancer symposium
摘要
美国第 2 6届圣安东尼奥乳腺癌会议于 2 0 0 3年 11月召开。现仅对会议有关乳腺癌外科治疗、细胞毒性化疗、内分泌治疗及放射治疗等方面的部分新进展作一简要综述。
出处
《国外医学（肿瘤学分册）》
2004年第9期695-698,共4页
Foreign Medical Sciences (Cancer Section)
参考文献20
-
1Jinno H, Ikeda T, Kitajima M, et al. Characteristics of breast cancer patients whose lymph node involvement was defined to sentinel lymph nodes only. Breast Cancer Res Treat,2003,82(Suppl 1) :S45. 被引量：1
-
2Kang SH, Kim SK, Kwon Y, et al. Decreased identification rate of sentinel lymph node after neoadjuvant chemotherapy. Breast Cancer Res Treat,2003,82 (Suppl 1 ): S173. 被引量：1
-
3Lohrisch C, Gelmon K, Speers C, et al. Delivery of adjuvant chemotherapy for breast cancer more than 12 weeks after definitive surgery may compromise survival. Breast Cancer Res Treat,2003,82(Suppl 1 ) :S27-S28. 被引量：1
-
4Venturini M, Aitini E, Del Mastro L, et al. Phase Ⅲ adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients: results from GONO-MIG1 study. Breast Cancer Res Treat, 2003,82(Suppl 1 ): S9. 被引量：1
-
5Martin M, Rodriguez Lescure A, Ruiz A, et al. Multicenter randomized phase Ⅲ study of adjuvant chemotherapy for axillary positive breast cancer ( APBC ) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8weekly paclitaxel (T) administrations: first safety analysis of GEICAM 9906 trial. Breast Cancer Res Treat,2003,82(Suppl 1 ): S29-S30. 被引量：1
-
6Roche H, Spielmann M, F umoleau P, et al. Safety analysis of the PA CS 01adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel taxotere for node positive breast cancer.Breast Cancer Res Treat,2003,82(Suppl 1): S32. 被引量：1
-
7Chen AM, Meric F, Hunt KK, et al. Breast-conserving therapy after neoadjuvant chemotherapy: the M. D. Anderson Cancer Center experience.Breast Cancer Res Treat,2003,82(Suppl 1 ) :S7-S8. 被引量：1
-
8Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appeers to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat,2003,82(Suppl 1 ): S6-S7. 被引量：1
-
9Dowsett M. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat, 2003, 82 ( Suppl 1):S7. 被引量：1
-
10Smith I,Dowsett M.Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat,2003,g2(Suppl 1):S6. 被引量：1
同被引文献8
-
1Nabhoitz JM,Pienkowski T,Mackey J,et al.Phase Ⅲ trial copparing TAC(docetaxel,doxorubicin,cyclophosphamide) with FAC(5-fluorouracil,doxorubicin,cyclophosphamide) in the adjuvant treatment of node positivw breast cancer(BC) patients:interim analysis of the BCIRG001 study[J].Proc Am Soc Clin Oncol,2002,21(6):141. 被引量：1
-
2Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21(6):976. 被引量：1
-
3Mamounas EP,Bryant J,Lembersky BC,et al.Paclitaxel(T) following doxorubicin/gyclophosphamide(AC)as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28[J].Proc Am Soc Clim Oncol,2003,22(2):12. 被引量：1
-
4Citron ML,Berry DA,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodepositive primary breast cancer:first report of intergroup trial C9741/ cancer and leukemia group B trial 9741[J].J Clin Oncol,2003,21(8):1 431. 被引量：1
-
5Jemal A,Murray T,Ward E,et al.Cancer statistics[J].CA Cancer J Clin,2005,55(1):10. 被引量：1
-
6Early Breast Cancer Trialists'Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for esrly breast cancer on recurrence and 15year survival:an overview of the randomised trials[J].Lancet,2005,365(9 472):1 687. 被引量：1
-
7何志高,陈洁,张丹.药物经济学研究中成本的确定[J].中国药房,1998,9(3):100-101. 被引量：148
-
8郭文萍.4种治疗前列腺炎方案的成本-效果分析[J].中国药房,2003,14(5):284-285. 被引量：17
-
1沈坤炜,沈镇宙.乳腺癌研究进展[J].中国肿瘤,2001,10(6):352-353. 被引量：2
-
2陈成钦.全国恶性淋巴瘤学术会议综述[J].癌症,1990,9(4):343-346. 被引量：1
-
3楼洪坤.第三届全国妇科肿瘤学术会议综述[J].中国肿瘤,1992,1(9):25-26.
-
4吴海鹰.血液肿瘤治疗研究进展──2000年 ASCO会议综述之八[J].癌症,2000,19(11):1051-1051.
-
5周志伟.结肠直肠癌化疗的研究进展——2001年ASCO会议综述之六[J].癌症,2001,20(11):1322-1322. 被引量：4
-
6徐兵河.乳腺癌治疗研究新进展[J].肿瘤研究与临床,2004,16(2):73-75. 被引量：11
-
7刘书盈.晚期非小细胞肺癌靶向治疗的优化[J].中华临床医师杂志（电子版）,2013,7(18):17-18. 被引量：3
-
8王合兵,窦拉加,张成武.HER-2过表达与乳腺癌治疗的研究进展[J].肿瘤学杂志,2008,14(2):151-153. 被引量：6
-
9霍小东(综述),王洪江(审校).食管癌分子靶向治疗[J].国际肿瘤学杂志,2009,36(1):40-42.
-
10张瑾,魏嘉阳.2015年圣安东尼奥国际乳腺癌研讨会回顾[J].中华乳腺病杂志（电子版）,2016,10(1):6-9. 被引量：2
